BRISBANE, Calif.--(BUSINESS WIRE)--
Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the third quarter ended September 30, 2016 after market close on Thursday, October 27, 2016. Innoviva management will host a webcast and conference call at 5:00 p.m. EDT that day to discuss the financial results and provide a corporate update.
To participate in the live call dial (877) 837-3908 from the U.S., or (973) 890-8166 for international callers and enter Conference ID: 97037854. A live webcast of the call will be available at: http://edge.media-server.com/m/p/6stsppn8 or from the investor relations section of the company website at www.inva.com and will be archived for 30 days. A telephone replay of the call will be available through Nov. 3, 2016, by dialing (855) 859-2056 from the U.S., or (404) 537-3406 for international callers and entering Conference ID: 97037854.
About Innoviva
Innoviva is focused on bringing compelling new medicines to patients in areas of unmet need by leveraging its significant expertise in the development, commercialization and financial management of bio-pharmaceuticals. Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®, which were jointly developed by Innoviva and GSK. Under the agreement with GSK, Innoviva is eligible to receive associated royalty revenues from RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and, if approved and commercialized, VI monotherapy, as well. In addition, Innoviva retains a 15 percent economic interest in future payments made by GSK for earlier-stage programs partnered with Theravance Biopharma, Inc. For more information, please visit Innoviva's website at www.inva.com.
ANORO®, RELVAR®, BREO® and ELLIPTA® are trademarks of the GlaxoSmithKline group of companies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161019005025/en/
